Abstract | OBJECTIVES: Guidelines recommend β-blockers and renin-angiotensin-aldosterone system blockers to improve long-term survival in hemodynamically stable myocardial infarction patients with a reduced left ventricular ejection fraction. The prevalence and outcomes associated with β and renin-angiotensin-aldosterone system blocker therapy in patients with ongoing cardiogenic shock is unknown. DESIGN: Secondary analysis of a randomized controlled trial. SETTING: INTERVENTIONS: None. PATIENTS: MEASUREMENTS AND MAIN RESULTS: The observed 30-day mortality among patients was higher in patients who received β or renin-angiotensin-aldosterone system blockers prior to cardiogenic shock resolution (27.3% vs 16.9%; adjusted hazard ratio, 2.36; 95% CI, 1.06-5.23; p = 0.035). Compared with patients not given β or renin-angiotensin-aldosterone system blockers, the 30-day mortality was higher among patients treated only with β-blockers (33.3% vs 16.9%, p = 0.017) but not among those only treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (18.2% vs 16.9%, p = 1.000). CONCLUSIONS: The administration of β or renin-angiotensin-aldosterone system blockers is common in North America and Europe in patients with myocardial infarction and cardiogenic shock prior to cardiogenic shock resolution. This therapeutic practice was independently associated with higher 30-day mortality, although a statistically significant difference was only observed in the subgroup of patients administered β-blockers.
|
Authors | Sean van Diepen, Harmony R Reynolds, Amanda Stebbins, Renato D Lopes, Vladimír Džavík, Witold Ruzyllo, Alexander Geppert, Petr Widimsky, E Magnus Ohman, Joseph E Parrillo, Harold L Dauerman, David A Baran, Judith S Hochman, John H Alexander |
Journal | Critical care medicine
(Crit Care Med)
Vol. 42
Issue 2
Pg. 281-8
(Feb 2014)
ISSN: 1530-0293 [Electronic] United States |
PMID | 23982033
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adrenergic beta-Antagonists
- Angiotensin Receptor Antagonists
- Mineralocorticoid Receptor Antagonists
- N(G)-monomethylarginine acetate
- Arginine
|
Topics |
- Adrenergic beta-Antagonists
(therapeutic use)
- Aged
- Angiotensin Receptor Antagonists
(therapeutic use)
- Arginine
(analogs & derivatives, therapeutic use)
- Double-Blind Method
- Female
- Heart Failure
(drug therapy, epidemiology, etiology)
- Humans
- Incidence
- Male
- Middle Aged
- Mineralocorticoid Receptor Antagonists
(therapeutic use)
- Renin-Angiotensin System
(drug effects)
- Shock, Cardiogenic
(complications)
- Time Factors
- Treatment Outcome
|